| Methods |
Crossover design; each phase 28 days. Not clear if intention to treat. Said to be double blind (vs placebo), but no other details. Concurrent asthma medication: inhaled steroids. |
| Participants |
Inclusion criteria: patients had asthma ‐ no diagnostic evidence; stable asthma medication implied. Patient details: 12 participants; age not stated; moderate asthma; no information on atopy or concurrent COPD. |
| Interventions |
3 interventions: oxitropium bromide 200µg, salbutamol 200µg and placebo; all interventions t.i.d. (not stated when). |
| Outcomes |
Daily symptom scores (unspecified, words only); FEV1 after 4 weeks. |
| Notes |
Abstract |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
Information not available (Cochrane Grade B) |
